A research funded by the AECC identifies two molecular types of cholangiocarcinoma, the most aggressive liver cancer

A research, funded with 1.2 million euros by the Spanish Association Against Cancer (AECC) Barcelona - Scientific Foundation, has established the molecular classification (genetic mechanism) of intrahepatic cholangiocarcinoma (ICC). This means an important advance in the search for an effective drug treatment. Today the only available treatment is surgery, and it is applicable only in the early stages of this disease. This cancer is resistant to any therapy and the second most frequent liver tumor. The investigation is led by Dr. Josep María Llovet, President of the International Liver Cancer Association (ILCA) and ICREA research professor at IDIBAPS, where he develops and coordinates most of the study, which has the support of two major international centers for treating liver cancer: Mount Sinai in New York and the National Cancer Institute in Milan.